



**COMPANY INFORMATION**

<b>Tickers</b>	CSE: SONA OTCQB: SNANF
<b>Website</b>	<a href="https://www.sonanano.com/">https://www.sonanano.com/</a>
<b>Corporate Address</b>	1969 Upper Water Street Suite 2001, Halifax, Nova Scotia B3J 3R7, Canada
<b>Linkedin</b>	<a href="https://www.linkedin.com/company/sona-nanotech-inc/">https://www.linkedin.com/company/sona-nanotech-inc/</a>
<b>Twitter</b>	<a href="https://twitter.com/sonananotech">https://twitter.com/sonananotech</a>
<b>YouTube</b>	<a href="https://www.youtube.com/channel/UCCK3VsReQEBrSY_gi5jWtFA">https://www.youtube.com/channel/UCCK3VsReQEBrSY_gi5jWtFA</a>
<b>Mentions (Twitter)</b>	@SonaNanotech
<b>Mentions LinkedIn</b>	@sona-nanotech-inc @david-regan-3a665b4 – David Regan, CEO

**Company Details**

<b>Company Email</b>	info@sonanano.com
<b>Contact Number</b>	1-902-442-0653
<b>Presentations</b>	<a href="https://www.sonanano.com/investor-presentations/">https://www.sonanano.com/investor-presentations/</a>
<b>Let's Connect</b>	<a href="https://www.sonanano.com/contact/">https://www.sonanano.com/contact/</a>
<b>Latest Press Releases</b>	<a href="https://www.sonanano.com/category/news-releases/">https://www.sonanano.com/category/news-releases/</a>

**About Sona Nanotech**

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) is a nanotechnology company in pre-clinical development of Targeted Hyperthermia Therapy (THT), a photothermal therapy which aims to eliminate tumors gently, from the inside out. By leveraging the power of nanotechnology, Sona Nanotech is working towards revolutionizing the approach to cancer therapies and diagnostics. With a commitment to innovation and research, the company is dedicated to improving outcomes for patients suffering from cancer.

Sona Nanotech's Targeted Hyperthermia Therapy uses nanoparticles and IR light to selectively destroy cancerous cells while minimizing damage to healthy tissues. This approach holds the potential to provide effective and targeted treatment options for patients, ultimately leading to improvement in both treatment outcomes and quality of life.

Sona Nanotech is actively conducting a study to assess the efficacy of Targeted Hyperthermia Therapy in treating colorectal cancer, breast cancer, and melanoma in mouse models alongside the Giacomantonio Immuno-Oncology Research Group. Sona Nanotech envisions a future where these advancements contribute to tangible improvements in cancer patient outcomes.


To learn more: <https://www.sonanano.com/>.

## Our Story

At Sona, our story is one of innovation, perseverance, and a deep-rooted commitment to improving lives through cutting-edge medical technology. Our journey has been fueled by a passionate team of scientists who strive to push the boundaries of what's possible. We are developing groundbreaking therapies and diagnostic solutions that harness the power of nanotechnology to transform patient outcomes. We invite you to delve into our inspiring story and witness the transformative impact we are aiming to make in the world of cancer treatment.


Discover more about our journey at: <https://www.sonanano.com/our-story/>

## Board of Directors & Leadership

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Chair	Mark Lievonen


### BIO

Mark Lievonen is an accomplished professional and a prominent figure in the biotechnology industry. He brings a wealth of expertise to his role as the Chair of Sona Nanotech, as the past president of Sanofi Pasteur Limited, a leading global vaccine manufacturer. His contribution to the field is further exemplified by his role as the Co-Chair of the Government of Canada's COVID-19 Vaccine Task Force, where he plays a pivotal role in guiding the country's vaccination strategy. In addition to his involvement with Sona Nanotech, Lievonen serves as a director for Quest PharmaTech, Biome Grow, and the Gairdner Foundation. With an MBA and as a Fellow of the Chartered Professional Accountants of Ontario (FCPA), Lievonen possesses strong business acumen and financial expertise, with his track record and portfolio of experience providing tremendous value to Sona Nanotech.

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Director	Walter Strapps


**BIO**

Walter Strapps is renowned in the field of biotechnology for his contributions to the development of antivirals and RNA therapeutics. As a Director of Sona Nanotech, Strapps brings a wealth of expertise and experience to the board. From his role as the CSO of Liberate Bio, a pioneering company focused on discovering lipid nanoparticle delivery vehicles, backed by Khosla Ventures. Prior to his role at Liberate Bio, Strapps held positions including CEO at Carver Bioscience and Chief Scientific Officer at Gemini Therapeutics. Strapps holds an M.A., M.Phil., and Ph.D. from Columbia University, underscoring his deep understanding of scientific research and development. His expertise in RNA therapeutics, coupled with his entrepreneurial spirit, make him an asset to Sona Nanotech.

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Director	Neil Fraser


**BIO**

As a Director at Sona Nanotech, Neil Fraser brings a wealth of experience in the healthcare and medical device sectors. As the past president of Medtronic Canada for 20 years, a leading medical technology company. Fraser contributed to the advancement of the Canadian healthcare landscape as a member of the Life Sciences Strategy Council for the Canadian Chamber of Commerce where he helped shape policies and strategies prior to his retirement. His involvement in Health Canada's Advisory Panel on Health Innovation further underscores his commitment to fostering innovation in healthcare. He is also a director at Cloud DX, a digital healthcare company. Fraser holds a B.A.Sc. and an MBA, combining technical knowledge with business acumen to make strategic contributions.

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Director	James Megann

**BIO**

James Megann is an experienced finance professional with a diverse background in venture capital, capital markets, and marketing bringing over 25 years of experience. Currently serving as the Managing Director of Numus Financial, he has completed over \$1.5 billion in transactions. Megann also serves on the board of Torrent Capital. With his knowledge of the communications and marketing industry, James brings perspective to Sona Nanotech's strategic initiatives. Notably, his community work has earned him recognition, including the Queens Diamond Jubilee medal in 2012.

<u>Image</u>	<u>Title</u>	<u>Name</u>
	Director & CSO	Len Pagliaro, PhD


**BIO**

Len Pagliaro, PhD serves as Chief Scientific Officer of Sona Nanotech Inc.

Based in Austin, Texas, Pagliaro is Sona's primary liaison with the U.S. Nanotechnology Characterization Laboratory, a public-private partnership between the National Cancer Institute, the Food and Drug Administration and the National Institute of Standards and Technology that seeks to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles.


An expert in the therapeutic uses of light, Pagliaro earlier served as CEO of Dynamic Light, a firm that leveraged dynamic light scattering for healthcare applications, including monitoring tissue perfusion during surgery. In a prior role, he was director of drug discovery and development at Thermo Fisher Scientific. He holds a U.S. patent for using electromagnetic radiation for surgical site disinfection.

Pagliaro earned a Ph.D. in cell biology and biochemistry from Wesleyan University and completed postdoctoral studies in biophysics and cell biology at Carnegie Mellon University.

<u>Image</u>	<u>Title</u>	<u>Name</u>
	CEO	David Regan

**BIO**

David Regan brings to his role as CEO significant experience as a strategy consultant, public company executive, and corporate director. With 10 years of experience in public companies, he has a deep understanding of strategy, investor relations, and corporate development. He has led Sona since 2020, closing four successful equity financing rounds, non-dilutive funding of \$4.1 million, and the 2023 acquisition of Siva Therapeutics, a U.S. based company. David graduated with an MBA from INSEAD and a BBA (Hons) from St. Francis Xavier University.


<u>Image</u>	<u>Title</u>	<u>Name</u>
	Co-Founder & Head Of Gnr R&D	Kulbir Singh, PhD

**BIO**

A co-founder of Sona Nanotech, Kulbir Singh, PhD heads research and development for Sona and is a co-inventor of the gold nanorods Sona uses in the firm's Targeted Hyperthermia Therapy™ cancer treatment, currently in preclinical trials. Targeted Hyperthermia Therapy™, or THT, generates therapeutic heat within solid tumors using Sona's proprietary gold nanorods and an infrared light device.

Earlier in his career, Singh co-founded GMS Surface Tech Ltd., where he developed new surfactant- and polymer-based scent-free cleaners. He also served as a research scientist at St. Francis Xavier University in Nova Scotia.

Singh holds a Ph.D. in Physical Chemistry from India's Guru Nanak Dev University and completed post-doctoral studies at St. Francis Xavier University.

<b>Image</b>	<b>Title</b>	<b>Name</b>
	Principal investigator on Sona's study evaluating the efficacy of Sona's technology & Scientific Advisor	Dr. Carman Giacomantonio, MD MSc FRCSC
<b>BIO</b>		
<p>Carman Giacomantonio, MD, MSc, FRCSC serves as the Principal Investigator of Sona Nanotech's preclinical efficacy study of Targeted Hyperthermia Therapy ("THT") treatment of triple negative breast cancer mouse tumors.</p> <p>A surgical oncologist and the author of more than 45 peer-reviewed articles, Giacomantonio heads the Giacomantonio Immuno-Oncology Research Group at Dalhousie University in Nova Scotia.</p> <p>Giacomantonio holds an M.Sc. in pathology and experimental pathology from Dalhousie University and earned an M.D. from Memorial University of Newfoundland. He completed postdoctoral studies in surgical oncology at the University of Calgary. A Fellow of the Royal College of Surgeons of Canada, he serves on the Board of Directors of the Canadian Cancer Society.</p>		

### **Technology Overview**


For a comprehensive understanding of Sona Nanotech's technologies, explore our Technology Overview page at <https://www.sonanano.com/technology-overview/>. This resource provides detailed insights into the innovative approaches we employ to drive potential advancements in the field of medical science. One notable aspect is the utilization of hyperthermia thermal therapy for cancer treatment, a concept that is discussed in the document "The Case for Hyperthermia Thermal Therapy for Cancer" available at <http://www.sonanano.com/wp-content/uploads/2023/06/The-Case-for-Hyperthermia-Thermal-Therapy-for-Cancer-Sona-Nanotech.pdf>. This informative document presents the scientific rationale and evidence supporting the efficacy of hyperthermia therapy in the context of cancer treatment. It discusses the principles behind Targeted Hyperthermia Therapy (THT) and its ability to selectively target and destroy cancer cells while sparing healthy tissues. Sona Nanotech's therapies offer a promising alternative or complementary approach to traditional cancer treatments. The Technology Overview page details our proprietary gold nanorods and their versatile applications in imaging and targeted drug delivery.

### **Therapies**

Sona Nanotech has been committed to pushing the boundaries of medical science through technology. Through our Targeted Hyperthermia Therapy (THT), we aim to revolutionize cancer treatment by using specially designed nanoparticles to selectively destroy cancer cells while minimizing harm to healthy tissue. Additionally, our proprietary gold nanorods provide a versatile

platform for a variety of potential applications, including imaging and targeted drug delivery. To learn more about our technology and their applications, visit our website at <https://www.sonanano.com/technology-overview/>. Explore our page on Targeted Hyperthermia Therapy (THT) to understand the transformative potential of this approach in cancer treatment: <https://www.sonanano.com/therapies/tht/>. Dive into our pre-clinical study section to gain insights into the research and development process behind our therapies: <https://www.sonanano.com/therapies/pre-clinical-study/>.

### **Key Partnerships**

<p>The National Cancer Institute's Nanotechnology Characterization Laboratory (NCL)</p>

<p>The National Cancer Institute's Nanotechnology Characterization Laboratory (NCL) has been instrumental in assisting Sona Nanotech in their assessment of Sona's GNR technology. By collaborating with the NCL, Sona Nanotech has gained access to critical resources and assessments. This assistance from the NCL helps Sona Nanotech validate the characteristics of its critical GNR materials. The collaboration with the NCL reinforces Sona Nanotech's commitment to rigorous scientific evaluation and helps to ensure that their technology meets the highest standards of safety.</p>
<p>1. <a href="https://www.sonanano.com/sona-nanotech-receives-technology-assessment-results-from-ncl/">https://www.sonanano.com/sona-nanotech-receives-technology-assessment-results-from-ncl/</a></p>
<p>2. <a href="https://www.sonanano.com/positive-results-of-second-assessment-of-sona-gnr-technology/">https://www.sonanano.com/positive-results-of-second-assessment-of-sona-gnr-technology/</a></p>
<p>3. <a href="https://www.sonanano.com/new-ncl-assessment-of-sona-gnr-technology-improvement-success/">https://www.sonanano.com/new-ncl-assessment-of-sona-gnr-technology-improvement-success/</a></p>